CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Investor Relations  /  Stock Exchange Disclosures  /  Press Release

PRESS RELEASE

Oct-20
08-OctBiocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi
Sep-20
31-AugBiocon appoints Anupam Jindal as its Chief Financial Officer
Aug-20
31-AugBiocon Biologics and Mylan Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
14-AugDisclosure of material impact of COVID 19 pandemic on the Company
03-AugExecution of SHA and SSA with Tata Capital Growth Fund II – Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015
Jul-20
31-JulTata Capital Growth Fund to Invest ~USD 30 Million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion
23-JulPress Release on financial results for the quarter ended June 30, 2020.
21-JulBiocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
11-JulBiocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
Jun-20
22-JunBiocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets
12-JunBiocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
05-JunKiran Mazumdar-Shaw wins EY World Entrepreneur of the Year™ 2020 Award. She is the first woman entrepreneur from India and third Indian to win this title in WEOY Award’s 20-year History
01-JunBiocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
May-20
27-MayBiocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients U.S. FDA recently approved CytoSorb for emergency use in COVID-19 patients
19-MayBiocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity Includes Drug Substance and Drug Product Facilities for Pegfilgrastim, Trastuzumab, and Bevacizumab
14-MayBiocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
12-MayCompany Statement: Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification
08-MayCompany Statement: Biocon’s Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection
Apr-20
28-AprBiocon and Mylan Launch Fulphila®d, Biosimilar Pegfilgrastim, in Canada.
16-AprCompany Statement : Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed
14-AprBiocon and Mylan Launch Fulphila®, Biosimilar Pegfilgrastim, in Australia
01-AprBiocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

FY: From April 1 – March 31

NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION
Share